Corcept Therapeutics Inc. Stock
We can see a decrease in the price for Corcept Therapeutics Inc.. Compared to yesterday it has lost -€1.400 (-1.360%).
With 16 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 125 € there is a positive potential of 23.52% for Corcept Therapeutics Inc. compared to the current price of 101.2 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -1.360% | 20.734% | 34.858% | 67.757% | 50.044% | 346.087% | 486.286% |
| Pacira Pharmaceuticals | 2.630% | 3.540% | 5.405% | 25.134% | 8.333% | -28.221% | -52.439% |
| Supernus Pharmaceuticals | -2.960% | -1.942% | -0.493% | 39.310% | -6.047% | 46.377% | 83.636% |
| Collegium Pharmaceutical Inc | -0.640% | 1.290% | -0.633% | 18.939% | -24.155% | 58.586% | 52.427% |
Comments
Corcept Therapeutics (CORT) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock, up from $88.00.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by HC Wainwright from $95.00 to $165.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better.
- Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Chief Financial Officer Mokari Atabak reported the sale of 40,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 15, 2026, according to an SEC Form 4 filing.
Transaction value
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
James N. Wilson, a director at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 10,000 shares of the company on July 15, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC